Correlation of NPM1 Type A Mutation Burden With Clinical Status and Outcomes in Acute Myeloid Leukemia Patients With Mutated NPM1 Type A

다국어 초록 (Multilingual Abstract)

Background: Nucleophosmin gene (NPM1) mutation may be a good molecular marker for assessing the clinical status and predicting the outcomes in AML patients. We evaluated the applicability of NPM1 type A mutation (NPM1-mutA) quantitation for this purpose.
Methods: Twenty-seven AML patients with normal karyotype but bearing the mutated NPM1 were enrolled in the study, and real-time quantitative PCR of NPM1-mutA was performed on 93 bone marrow (BM) samples (27 samples at diagnosis and 56 at follow-up). The NPM1-mutA allele burdens (represented as the NPM1-mutA/Abelson gene (ABL) ratio) at diagnosis and at follow-up were compared.
Results: The median NPM1-mutA/ABL ratio was 1.3287 at diagnosis and 0.092 at 28 days after chemotherapy, corresponding to a median log10 reduction of 1.7061. Significant correlations were observed between BM blast counts and NPM1-mutA quantitation results measured at diagnosis (γ=0.5885, P=0.0012) and after chemotherapy (γ=0.5106, P=0.0065). Total 16 patients achieved morphologic complete remission at 28 days after chemotherapy, and 14 (87.5%) patients showed a >3 log10 reduction of the NPM1-mutA/ABL ratio. The NPM1-mutA allele was detected in each of five patients who had relapsed, giving a median increase of 0.91-fold of the NPM1-mutA/ABL ratio at relapse over that at diagnosis.
Conclusions: The NPM1-mutA quantitation results corresponded to BM assessment results with high stability at relapse, and could predict patient outcomes. Quantitation of the NPM1-mutA burden at follow-up would be useful in the management of AML patients harboring this gene mutation.

참고문헌 (Reference)

1 Sabattini E, "WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview" 102 : 83-87, 2010

2 Shayegi N, "The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML" 122 : 83-92, 2013

3 Grimwade D, "The clinical significance of cytogenetic abnormalities in acute myeloid leukaemia" 14 : 497-529, 2001

4 Walter RB, "Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission" 122 : 1813-1821, 2013

5 Grimwade D, "Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials" 116 : 354-365, 2010

6 Cilloni D, "Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study" 27 : 5195-5201, 2009

7 Gorello P, "Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations" 20 : 1103-1108, 2006

8 Bene MC, "Proposals for the immunological classification of acute leukemias" 9 : 1783-1786, 1995

9 Ostronoff F, "Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute/Medical Research Council report" 33 : 1157-1164, 2015

10 Patel JP, "Prognostic relevance of integrated genetic profiling in acute myeloid leukemia" 366 : 1079-1089, 2012

11 Palmisano M, "NPM1 mutations are more stable than FLT3 mutations during the course of disease in patients with acute myeloid leukemia" 92 : 1268-1269, 2007

12 Dvorakova D, "Monitoring of minimal residual disease in acute myeloid leukemia with frequent and rare patient-specific NPM1 mutations" 85 : 926-929, 2010

13 Kern W, "Monitoring of minimal residual disease in acute myeloid leukemia" 112 : 4-16, 2008

14 Krönke J, "Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group" 29 : 2709-2716, 2011

15 Alpermann T, "Molecular subtypes of NPM1 mutations have different clinical profiles, specific patterns of accompanying molecular mutations and varying outcome in intermediate risk acute myeloid leukemia" 101 : e55-e58, 2016

16 Falini B, "Molecular and alternative methods for diagnosis of acute myeloid leukemia with mutated NPM1: flexibility may help" 95 : 529-534, 2010

17 Yin JA, "Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial" 120 : 2826-2835, 2012

18 Schnittger S, "Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML" 114 : 2220-2231, 2009

19 Paietta E, "Minimal residual disease in acute myeloid leukemia: coming of age" 2012 : 35-42, 2012

20 Stentoft J, "Kinetics of BCR-ABL fusion transcript levels in chronic myeloid leukemia patients treated with STI571 measured by quantitative real-time polymerase chain reaction" 67 : 302-308, 2001

21 Craig FE, "Flow cytometric immunophenotyping for hematologic neoplasms" 111 : 3941-3967, 2008

22 Döhner H, "Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet" 115 : 453-474, 2010

23 Falini B, "Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype" 352 : 254-266, 2005

24 Harrison CJ, "Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12" 28 : 2674-2681, 2010

25 Mrózek K, "Cytogenetics in acute leukemia" 18 : 115-136, 2004

26 Park SH, "CEBPA single mutation can be a possible favorable prognostic indicator in NPM1 and FLT3-ITD wild-type acute myeloid leukemia patients with intermediate cytogenetic risk" 37 : 1488-1494, 2013

27 Ivey A, "Assessment of minimal residual disease in standard-risk AML" 374 : 422-433, 2016

28 Löwenberg B, "Acute myeloid leukemia" 341 : 1051-1062, 1999